Renal cell therapy in the treatment of patients with acute and chronic renal failure

Blood Purification

Volumn 22, Issue 1, 2004, Pages 60-72

  Humes, H David ^a   Weitzel, William F ^a   Fissell, William H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bioartificial organs; Cytokines; End stage renal disease; Inflammation; Renal tubule assist device; Tubular necrosis, acute

Indexed keywords

CYTOKINE;

ACUTE KIDNEY FAILURE; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; ARTIFICIAL KIDNEY; BIOARTIFICIAL ORGAN; BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISEASE COURSE; GENE EXPRESSION; HEMOFILTRATION; HUMAN; KIDNEY TUBULE CELL; LABORATORY TEST; LEUKOCYTE; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; BIOARTIFICIAL ORGANS; CELLS, CULTURED; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOKINES; EQUIPMENT DESIGN; FASCIITIS, NECROTIZING; GENE EXPRESSION PROFILING; HEMOFILTRATION; HUMANS; INFLAMMATION; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; KIDNEY, ARTIFICIAL; MALE; MULTIPLE ORGAN FAILURE; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 0942278986     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074925     Document Type: Article

References (45)

1. Humes HD: Cell therapy: Leveraging nature's therapeutic potential. J Am Soc Nephrol 2003;14:2211-2213.
2. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Solomon B, Demetriou AA: Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484-491.
3. Maki T, Otsu I, O'Neil JJ, Dunleavy K, Mullon CJ, Solomon BA, Monaco AP: Treatment of diabetes by xenogeneic islets without immuno-suppression. Use of a vascularized bioartificial pancreas. Diabetes 1996;45:342-347.
4. Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF: Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 1999;17:451-455.
5. Mehta RL: Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. Semin Nephrol 1994;14:64-82.
6. Excerpts from United States Renal Data System. Annual Data Report. Am J Kidney Dis 1998;32(suppl):569-580.
7. Humes HD: Bioartificial kidney for full renal replacement therapy. Semin Nephrol 2000;20: 71-82.
8. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-348.
9. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693.
10. Breen D, Bihari D: Acute renal failure as a part of multiple organ failure: The slippery slope of critical illness. Kidney Int 1998;53(suppl 66):S25-S33.
11. Bishop GA, Waugh JA, Hall BM: Expression of HLA antigens on renal tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation 1988;46:303-310.
12. Wuthrich RP, Yui MA, Mazoujian G, Nabavi N, Glimcher LH, Kelley VE: Enhanced MHC class II expression in renal proximal tubules preceded loss of renal function in MRL//pr mice with lupus nephritis. Am J Pathol 1989;134:45-51.
13. Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE: Generation of highly differentiated murine renal tubular epithelial cell lines: MHC class II regulation, antigen presentation and tumor necrosis factor production. Kidney Int 1990;37:783-792.
14. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, Wuthrich RP: Renal tubular epithelial expression of the costimulatory molecule B7RP-1(inducible costimulator ligand). J Am Soc Nephrol 2002;13:1517-1526.
15. Boswell RN, Yard BA, Schrama E, van Es LA, Daha MR, van der Woude FJ: Interleukin 6 production by human proximal tubular epithelial cells in vitro: Analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant 1994;9:599-606.
16. Leonard M, Ryan MP, Watson AJ, Schramek H, Healy E: Role of MAP kinase pathway in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney Int 1999;56:1366-1377.
17. Yard BA, Daha MR, Kooymans-Couthino M, Bruijn JA, Paape ME, Schrama E, Vanes LA, van der Woude FJ: IL-1 alpha stimulated TNF alpha production by cultured human proximal tubular epithelial cells. Kidney Int 1992;42:383-389.
18. van Kooten C, van der Linde X, Woltman AM, van Es LA, Daha MR: Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int 1999;56:41-51.
19. Prodjosudjadi W, Gerritsma JS, Klar-Mohamed N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 1995;48:1477-1486.
20. Kimmel PL, Philliphs TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236-244.
21. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
22. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
23. Himmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002;61:705-716.
24. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure: Kidney Int 2000;58:2571-2578.
25. Nikolovski J, Gulari E, Humes HD: Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 1999;8:351-364.
26. MacKay SM, Funke AJ, Buffington DA, Humes HD: Tissue engineering of a bioartificial renal tubule. ASAIO J 1998;44:179-183.
27. Humes HD, MacKay SM, Funke AJ, Bufffington DA: Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. Kidney Int 1999;55:2502-2514.
28. Humes HD, Fissell WH, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM: Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 2002;39:1078-1087.
29. Henderson B, Poole S, Wilson M: Bacteria-Cytokine Interactions in Health and Disease. London, Portland Press, 1998.
30. De Vriese A, Vanholder R, De Sutter J, Colardyn F, Lameire N: Continuous renal replacement therapies in sepsis: Where are the data? Nephrol Dial Transplant 1998;13:1362-1364.
31. Schetz M: Non-renal indications for continuous renal replacement therapy. Kidney Int 1999;56:S88-S94.
32. Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 1993;269:390-391.
33. Stevens DL: Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000;51:271-288.
34. Norrby-Teglund A, Lustig R, Kotb M: Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates. Infect Immun 1997;65:5209-5215.
35. Thakar CV, Yared JP, Worley S, Cotman K, Paganini EP: Renal dysfunction and serious infections after open-heart surgery. Kidney Int 2003;64:239-246.
36. Fissell WH, Dyke DB, Buffington DA, Weitzel WF, Westover AJ, MacKay SM, Gutierrez JM, Humes HD: Bioartificial kidney alter cytokine response and hemodynamics in endotoxin-challenged dogs. Blood Purif 2002;20:55-60.
37. Saxén L: Organogenesis of the Kidney. New York, Cambridge University Press, 1987.
38. Turpen JB, Knudson CM: Ontogeny of hematopoietic cells in Rana pipiens: Precursor cell migration during embryogenesis. Dev Biol 1982;89:138-151.
39. Zapata A: Ultrastructural study of the teleost fish kidney. Dev Comp Immunol 1979;3:55-65.
40. Smith AM, Potter M, Merchant EB: Antibody-forming cells in the pronephros of the teleost Lepomis macrochirus. J Immunol 1967;99:876-882.
41. Irving P, Troxler L, Heuer TS, Belvin M, Kopczynski C, Reichhart JM, Hoffmann JA, Hetru C: A genome-wide analysis of immune responses in Drosophila. Proc Natl Acad Sci USA 2001;98:15119-15124.
42. Chinnaiyan AM, Huber-Lang M, Kumar-Sinha C, Barrette TR, Shankar-Sinha S, Sarma VJ, Padgaonkar VA, Ward PA: Molecular signatures of sepsis: Multiorgan gene expression profiles of systemic inflammation. Am J Pathol 2001;159:1199-1209.
43. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, Botstein D, Staudt LM, Brown PO, Relman DA: Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA 2002;99:972-977.
44. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2068-2070.
45. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, Fissell WH: Cell therapy with a tissue-engineered kidney protects against the multi-organ consequences of septic shock. Crit Care Med 2003;31:2421-2428.